MDB Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
MongoDB Inc (MDB) does not present a compelling buy opportunity for a beginner, long-term investor at this time. While the company has strong growth potential in the AI and cloud computing space, technical indicators are bearish, insider selling has increased significantly, and short-term stock trends suggest further downside. The lack of Intellectia Proprietary Trading Signals also indicates no immediate trading opportunity.
The MACD histogram is positive but contracting, indicating weakening momentum. The RSI is neutral at 26.439, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is trading below key support levels (S1: 245.594), with resistance at R1: 275.72. Short-term trends suggest a 60% probability of further declines (-0.62% in the next day, -3.05% in the next week, -5.58% in the next month).
Mizuho upgraded the stock to Outperform with a price target of $325, citing strong customer growth and AI-related tailwinds.
Hedge funds have significantly increased their buying activity (+273.15% last quarter).
The company appointed a new Chief Revenue Officer to strengthen its AI and cloud computing market leadership.
Insiders are selling heavily, with a 609.95% increase in selling activity over the last month.
Analysts have broadly reduced price targets, citing valuation concerns and conservative fiscal 2027 guidance.
The stock is trading at a premium compared to peers, leaving little room for growth deceleration.
In Q4 2026, revenue increased by 26.75% YoY to $695.07M, but net income dropped by 1.87% YoY to $15.53M. EPS also declined by 5.00% YoY to $0.19. Gross margin improved slightly to 73.04%, up 0.29% YoY. While revenue growth is strong, profitability metrics are under pressure.
Recent analyst ratings are mixed. Mizuho and Scotiabank upgraded the stock to Outperform, citing AI tailwinds and customer growth. However, firms like Morgan Stanley, Goldman Sachs, and UBS lowered their price targets, highlighting valuation concerns and conservative guidance. The consensus price target range is $275-$335.
